Back to Annual Meeting

Back to Annual Meeting

Abstract #155243

Nicole A. Lamparello¹, Emily M. Herzberg¹, Allison C. Boyd¹, Mariah M. Marshall¹, Miguel A. DeLeon¹, Allison Porter¹, Debra Dekker, PhD², Charles H. Evans, MD, PhD¹, and Michael Relf, PhD, RN³. (1) Dept. of Human Science, Georgetown University, 3700 Reservoir Road NW, School of Nursing & Health Studies, Washington, DC 20057, 908.581.4526, nal5@georgetown.edu, (2) Whitman-Walker Clinic, 1701 14th Street NW, Elizabeth Taylor Health Center, Washington, DC 20009, (3) Department of Nursing, Georgetown University, 3700 Reservoir Road NW, Washington, DC 20057-1107

Background: When HIV-1 positive individuals engage in high-risk behaviors, the possibility of transmitting drug resistant variants of the HIV-1 virus increases. Recent literature has documented varied rates of HIV-1 genotypic mutations resulting in a reduction in viral susceptibility to anti-retroviral therapy (ART) among treatment-naïve individuals. The rates of genotypic resistance among treatment-naïve HIV-1-infected individuals in Washington, DC, the area with the highest rate of HIV/AID in the US, are poorly documented. A pilot study was designed to determine the rates of ART resistance in a retrospective sample of treatment-naïve individuals in Washington, DC. Methods: From January 1, 2005 to December 31, 2005, there were 231 new patients, 117 of who were HIV-1 treatment-naïve, and 49 who had HIV-1 genotypic analyses before the individuals voluntarily entered medical care. After correcting for missing medical charts and genotype reports, 42 treatment-naïve HIV-1 infected individuals were identified. Results: Preliminary results indicate that individuals in Washington, DC are infected with resistant HIV-1. Genotypic mutations are also present in the regions of the virus genome whose gene products are the targets for anti-retroviral drugs. Further analysis is underway to examine the rates for clinically relevant mutations, as well as the correlate factors associated with genotypic mutations (high-risk behaviors and demographic variables). Conclusions: These results have important public health implications and validate the need to further investigate the rates of resistance in metropolitan areas such as Washington, DC.

Learning Objectives: At the end of the presentation, the participants will be able to

• describe the rates of genotypic ARV resistance among a sample of treatment-naive HIV-1 infected individuals
• describe correlates of genotypc ARV resistance among a sample of treatment-naive HIV-1 infected individuals

Keywords: Antiretroviral Combination Therapy, HIV/AIDS

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.